Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine - 12/12/21
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Background |
Irritable bowel syndrome (IBS) is a functional gastrointestinal condition marked by chronic bowel pain or discomfort, as well as changes in abdominal motility. Despite its worldwide prevalence and clinical impact, the cause of IBS is unknown. Inflammation could play a fundamental role in the development of IBS. The aim of this study was to examine whether pentoxifylline, a competitive nonselective phosphodiesterase inhibitor, is useful in alleviating abdominal pain in IBS patients treated with mebeverine.
Methods |
A randomized, controlled, and prospective clinical study that included 50 outpatients who met the inclusion criteria for IBS. Patients are allocated randomly into two groups (n = 25). Group 1 (mebeverine group) received mebeverine 135 mg three times daily (t.i.d) for three months. Group 2 (pentoxifylline group) received mebeverine 135 mg t.i.d and pentoxifylline 400 mg two times daily for three months. Patients were assessed by a gastroenterologist at baseline and three months after the medication had been started. The serum levels of interleukin-6, interleukin-8 and tumor necrosis factor-alpha, fecal Neutrophil Gelatinase Associated Lipocalin (NGAL), and fecal myeloperoxidase were measured at the start and after three months of therapy. The Numeric Pain Rating scale (NRS) was assessed at baseline and after therapy. Results: the pentoxifylline group showed a significant decrease in the level of measured biomarkers and a significant decrease in NRS.
Conclusion |
Pentoxifylline could be a promising adjuvant anti-inflammatory drug in the treatment of abdominal pain in IBS patients treated with mebeverine.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Irritable Bowel Syndrome is a gastrointestinal condition marked by flatulence, abdominal cramps, and changes in bowel habits. |
• | Low grade mucosal inflammation is proven to be involved in irritable bowel syndrome which leads to release of cytokines. |
• | Pentoxifylline decreases the levels of cytokines by its anti-inflammatory effect and could be a novel adjunctive to antispasmodics in relieving abdominal pains in Irritable Bowel Syndrom. |
Keywords : Phosphodiesterase inhibitors, IBS, Pentoxifylline, Inflammation, Visceral Hypersensitivity
Plan
| ☆ | Trial registration identifier: NCT04217733. |
Vol 145
Article 112399- janvier 2022 Retour au numéro
Article précédent
- DA-9805 protects dopaminergic neurons from endoplasmic reticulum stress and inflammation
- Sora Kang, Ying Piao, Young Cheol Kang, Suyeol Lim, Youngmi Kim Pak
- Trans-eQTLs of the CYP3A4 and CYP3A5 associated with tacrolimus trough blood concentration in Chinese renal transplant patients
- Huijie Lu, Haixia Jiang, Siyao Yang, Chengcheng Li, Chuanjiang Li, Ruifan Shao, Pai Zhang, Daoyi Wang, Zhiwei Liu, Huana Qi, Yinuan Cai, Wenbin Xu, Xiaojie Bao, Hailan Wang, Liang Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?